Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanobiotix ( (NBTX) ) just unveiled an announcement.
On September 12, 2025, Nanobiotix announced its updated voting rights and share capital information, reporting 48,236,771 shares outstanding as of August 31, 2025. The announcement, in compliance with French financial regulations, provides transparency to stakeholders and reinforces the company’s commitment to regulatory standards, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (NBTX) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company based in Paris, France, specializing in physics-based therapeutic approaches aimed at improving treatment outcomes. Founded in 2003, the company is listed on Euronext Paris and the Nasdaq Global Select Market, with subsidiaries in Cambridge, Massachusetts, and other locations. Nanobiotix owns over 25 patent families related to nanotechnology platforms with applications in oncology, bioavailability, biodistribution, and central nervous system disorders.
Average Trading Volume: 9,719
Technical Sentiment Signal: Buy
Current Market Cap: $478.2M
See more data about NBTX stock on TipRanks’ Stock Analysis page.